Ensysce Biosciences Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
ENSC$0.36-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
| Stockholders’ Equity (Deficit) | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Additional | ||||||
| Number of Shares | Amount | Paid-In Capital | Accumulated Deficit | Noncontrolling interests | Total | |
| Balance on March 31, 2023 | 1,284,583 | $128 | $113,293,834 | $(113,127,237) | $(319,149) | $(152,424) |
| Settlement of restricted stock units | 312 | - | - | - | - | - |
| Public offering, net | 1,084,000 | 109 | 6,360,843 | - | - | 6,360,952 |
| Transaction costs associated with public offering | - | - | (253,836) | - | - | (253,836) |
| Issuance of common stock upon exercise of warrants | 300,897 | 30 | (30) | - | - | - |
| Stock-based compensation | - | - | 77,417 | - | - | 77,417 |
| Deemed dividend related to warrants down round provision | - | - | 3,729 | (3,729) | - | - |
| Net loss | - | - | (2,232,242) | (7,060) | (2,239,302) | |
| Balance on June 30, 2023 | 2,669,792 | $267 | $119,481,957 | $(115,363,208) | $(326,209) | $3,792,807 |
| Balance on March 31, 2024 | 7,329,172 | $733 | $128,422,232 | $(124,673,853) | $(328,483) | $3,420,629 |
| Issuance of common stock upon warrant inducement | 822,000 | 82 | (82) | - | - | - |
| Stock-based compensation | - | - | 26,549 | - | - | 26,549 |
| Net Loss | - | - | - | (1,967,793) | - | (1,967,793) |
| Balance on June 30, 2024 | 8,151,172 | $815 | $128,448,699 | $(126,641,646) | $(328,483) | $1,479,385 |
| Balance on December 31, 2022 | 534,490 | $53 | $107,216,566 | $(110,931,063) | $(315,208) | $(4,029,652) |
| Settlement of restricted stock units | 624 | - | - | - | - | - |
| Settlement of commitment fee | 44,444 | 4 | 399,996 | - | - | 400,000 |
| Conversion of convertible notes | 408,580 | 41 | 3,056,851 | - | - | 3,056,892 |
| Public offerings, net | 1,381,619 | 139 | 9,049,865 | - | - | 9,050,004 |
| Transaction costs associated with public offerings | - | - | (447,879) | - | - | (447,879) |
| Issuance of common stock upon exercise of warrants | 300,897 | 30 | (30) | - | - | - |
| Stock-based compensation | - | - | 194,550 | - | 194,550 | |
| Reverse split fractional shares | (862) | - | - | - | - | - |
| Deemed dividend related to warrants down round provision | - | - | 12,038 | (12,038) | - | - |
| Net loss | - | - | - | (4,420,107) | (11,001) | (4,431,108) |
| Balance on June 30, 2023 | 2,669,792 | $267 | $119,481,957 | $(115,363,208) | $(326,209) | $3,792,807 |
| Balance on December 31, 2023 | 3,146,076 | $315 | $121,233,901 | $(121,557,074) | $(328,409) | $(651,267) |
| Settlement of restricted stock units | 63 | - | - | - | - | - |
| Conversion of convertible notes | 745,521 | 75 | 1,168,525 | - | - | 1,168,600 |
| Issuance of common stock upon exercise of warrants | 1,323,904 | 132 | 2,075,087 | - | - | 2,075,219 |
| Issuance of common stock upon warrant inducement, net of issuance costs | 2,935,608 | 293 | 4,718,002 | - | - | 4,718,295 |
| Transaction costs associated with warrant inducement | - | - | (806,862) | - | - | (806,862) |
| Stock-based compensation | - | - | 59,756 | - | - | 59,756 |
| Deemed dividend related to warrants down round provision | - | - | 290 | (290) | - | - |
| Net loss | - | - | - | (5,084,282) | (74) | (5,084,356) |
| Balance on June 30, 2024 | 8,151,172 | $815 | $128,448,699 | $(126,641,646) | $(328,483) | $1,479,385 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.